Investor FAQs

Investor FAQs

Show All
What does Exagen do?
We are dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway that is widely implicated across many autoimmune and autoimmune related diseases, including systemic lupus erythematosus, or SLE. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Our strategy includes leveraging our portfolio of testing products to market therapeutics through our sales channel and targeting the approximately 5,000 rheumatologists across the United States. Our business model of integrating testing products and therapeutics positions us to offer targeted solutions to rheumatologists and, ultimately, better serve patients.
Where is Exagen incorporated?
Exagen was incorporated in New Mexico in 2002 and subsequently incorporated in Delaware in 2003.
Where is Exagen’s corporate headquarters?
Exagen’s corporate headquarters is located at 1261 Liberty Way, Suite C, Vista, California 92081
On what exchange does Exagen’s stock trade? What is Exagen’s stock ticker?
Exagen is traded on the NASDAQ Exchange under the ticker symbol XGN.
What is Exagen’s CUSIP number?
Exagen’s CUSIP number is 30068X103.
Who is Exagen’s transfer agent, and how do I contact them?
Exagen uses Computershare as its transfer agent and contact information is provided below.

Computershare
P.O. Box 505000
Louisville, KY 40202
(800) 736-3001 (U.S., Canada, Puerto Rico)
+1 (781) 575-3100 (Non U.S.)
Does Exagen pay a dividend?
Exagen does not pay a cash dividend and does not foresee paying any cash dividends in the foreseeable future.
How can I purchase Exagen common stock?
Shares of Exagen can be purchased through a broker or stock purchase service of your preference.
Does Exagen have a direct stock purchase plan?
Exagen does not currently have a direct stock purchase plan.
Whom do I contact with questions about my stock?
Please contact your registered broker.
What is Exagen’s fiscal year-end?
Our fiscal year ends December 31.
Who is Exagen’s independent registered public accounting firm?
Exagen’s independent public accounting firm is BDO USA, LLP.
Who is Exagen’s legal counsel?
Exagen’s legal counsel is Latham & Watkins.
Who makes up the Exagen Management team and Board of Directors?
To view Exagen’s Management team and Board of Directors please visit the Management and Board of Directors sections of this website.
Does Exagen have a corporate governance program?
Yes, to review Exagen’s corporate governance policies, please visit the Corporate Governance section of this website.
When is your next earnings release?
Exagen will issue a press release that includes the date of our quarterly earnings call. These releases will be posted on the News and Press Releases section of our website, including the details for accessing the conference call and/or webcast to discuss the results.
How can I get copies of financial documents on the company, including quarterly reports (Form 10-Q) and annual reports (Form 10-K)?
Quarterly and annual reports and other investor materials are available under the SEC Filings page of the Investors section of the corporate website. Additionally, all SEC filings can also be viewed directly on the SEC website.
How can I receive financial update emails?
To sign up to automatically receive Exagen’s financial information by e-mail, please visit the Email Alerts section of this website.
How can I find out more about upcoming events?
Please see the Events page of this website.
How do I contact EXAGEN Investor Relations?
If you wish to contact Exagen’s investor relations team, please send an email to ir@exagen.com.